InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (6 ops.)
Discover the detailed record of transactions filed by SOFINNOVA PARTNERS SAS, Partner, Sofinnova Partners - Crossover Strategy. Officer active across 5 companies, notably ABIVAX. Aggregated, 32 filings have been recorded. Total volume traded: €235.5m. The latest transaction was filed on 28 January 2026 — Souscription. Regulator: AMF. The full history is free.
Declarations32 total
€3m10,714,285 shares@ €0.2811.8% of flow
ActionEuronext Growth Paris
2026DD1091922·
US$116m950,000 shares@ US$122.40791.23% mcap39.2% of flow
American Depositary SharesNasdaq Global Market (US)
2026DD1089198·
€56m590,877 shares@ €94.1640.59% mcap18.8% of flow
American Depositary SharesNasdaq Global Market
2025DD1066576·
US$56m590,877 shares@ US$94.1640.59% mcap18.8% of flow
American Depositary SharesNasdaq Global Market
2025DD1066880·
US$17m270,000 shares@ US$64.005.8% of flow
American Depositary SharesNasdaq Global Market
2025DD1050946·
€1m5,882,353 shares@ €0.175.2% of flow
Actions à bons de souscription d'actionsEuronext Paris
2025DD1046658·
€200,000889,680 shares@ €0.22481.0% of flow
Actions à bons de souscription d'actionsEuronext Paris
2025DD1025162·
€750,0002,663,353 shares@ €0.28163.9% of flow
Actions à bons de souscription d'actionsEuronext Paris
2025DD1013140·
€987,9342,812,223 shares@ €0.35135.1% of flow
Actions à bons de souscription d'actionsEuronext Paris
2024DD1004364·
€2m5,063,291 shares@ €0.39510.4% of flow
Actions à bons de souscription d'actionsEuronext Paris
2024DD965281·
€1,000,0001,587,301 shares@ €0.633.9% of flow
ActionEuronext Growth Paris
2024DD960175·
€7m12,280,701 shares@ €0.5727.5% of flow
ActionEuronext Growth Paris
2024DD950579·
€2m5,224,660 shares@ €0.382810.4% of flow
ActionEuronext Paris
2024DD950181·
€69,733110,740 shares@ €0.62975.1% of flow
ActionEuronext Growth Paris
2024DD945371·
€2m3,038,279 shares@ €0.712211.3% of flow
Titre de créanceEuronext Paris
2023DD939161·
€14m1,200,000 shares@ €11.604.7% of flow
ActionNasdaq Global Market
2023DD934449·
US$14m1,200,000 shares@ US$11.604.7% of flow
ActionNasdaq Global Market
2023DD935816·
€2m21 shares@ €100,000.0010.9% of flow
Titre de créanceHors plateforme de négociation
2023DD925700·
€7m25,000,000 shares@ €0.2827.5% of flow
ActionEuronext Growth Paris
2023DD923626·
€10m1,535,000 shares@ €6.503.4% of flow
ActionEuronext Paris
2023DD887610·
€309,5201 shares@ €309,520.000.1% of flow
Titre de créanceHors plateforme de négociation
2022DD860017·
€5m584,000 shares@ €8.360.052% mcap1.6% of flow
ActionEuronext Paris
2022DD859590·
Ideal exit: 30 May 2023 (T+270)
US$2m138,880 shares@ US$14.3710.26% mcap16.6% of flow
ActionNASDAQ
2021DD783824·
Ideal exit: 26 Jun 2022 (T+270)
€8m261,865 shares@ €30.552.7% of flow
ActionEuronext Paris
2021DD765910·
€8m7,500,000 shares@ €1.0029.4% of flow
Obligations convertiblesEuronext Growth Paris
2021DD744035·
25 of 32 declarations
About SOFINNOVA PARTNERS SAS
SOFINNOVA PARTNERS SAS is a life sciences venture capital firm, and its most visible representative in listed biotech companies is Kinam Hong, a Partner in the Crossover Strategy. He joined Sofinnova Partners in January 2017 and has since played a leading role in supporting later-stage biopharmaceutical companies across Europe and internationally. Before Sofinnova, Kinam Hong was co-manager of the Exane Equinox Fund, a global healthcare fund focused on public biotechnology companies. He spent the prior decade as an investor and equity research analyst covering biotech, including at Citigroup Investment Research. Earlier in his career, he worked at Sanofi in new product development, gaining hands-on experience in product development, business development, strategic marketing, and China strategy. Kinam Hong holds degrees in molecular biology/biochemistry and medicine from the University of Florida, as well as a CFA designation and an MBA from INSEAD. This combination of medical, scientific, and financial training is particularly well suited to crossover investing, where capital allocation decisions depend on the quality of clinical data, regulatory visibility, management execution, and balance-sheet discipline. Within Sofinnova Partners, he has been associated with several high-profile portfolio companies, including Abivax, Sensorion, and GenSight Biologics, reflecting the firm’s strong footprint in European listed life sciences. At Abivax, he served as Sofinnova Partners’ permanent representative on the board of directors, contributing to governance and strategic oversight at a critical stage of the company’s development. Sofinnova has also been an active investor in Sensorion through multiple financing transactions, while its involvement with GenSight Biologics further demonstrates a long-term commitment to innovative companies in ophthalmology, ENT, and immunology. More broadly, Kinam Hong is recognized for a hands-on investment style, close engagement with management teams, and the ability to combine clinical understanding with public-market discipline. His work reflects Sofinnova’s broader strategy: partnering with ambitious entrepreneurs and helping scale breakthrough healthcare companies through complex growth and financing milestones.
